Viatris (XSWX:VTRS) Other Current Liabilities: CHF738 Mil (As of Mar. 2026)


XSWX:VTRS Viatris Inc XSWX:VTRS
60 GF Score
Price CHF13.06
GF Value CHF8.89
! 8 Warning Signs
View Full Analysis

What is Viatris Other Current Liabilities?

Viatris XSWX:VTRS +0.62% 60 Other Current Liabilities is CHF738 Mil as of Mar. 2026. GuruFocus rates XSWX:VTRS with a GF Score™ of 60/100 and a GF Value™ of CHF8.89. The stock has 8 warning signs investors should review.

Viatris's other current liabilities for the quarter that ended in Mar. 2026 was CHF738 Mil.

Viatris's quarterly other current liabilities declined from Sep. 2025 (CHF814 Mil) to Dec. 2025 (CHF789 Mil) and declined from Dec. 2025 (CHF789 Mil) to Mar. 2026 (CHF738 Mil).

Viatris's annual other current liabilities declined from Dec. 2023 (CHF1,217 Mil) to Dec. 2024 (CHF1,195 Mil) and declined from Dec. 2024 (CHF1,195 Mil) to Dec. 2025 (CHF789 Mil).

Viatris Other Current Liabilities Related Terms

Viatris Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Viatris's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Other Current Liabilities Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,298.98 1,153.41 1,216.52 1,195.19 788.85

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,033.55 1,073.83 814.33 788.85 738.33
XSWX:VTRS
60GF Score
Viatris Inc XSWX:VTRS
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of CHF738 Mil mean?
Viatris (XSWX:VTRS) has a Other Current Liabilities of CHF738 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Viatris.
Is Viatris' Other Current Liabilities too high?
Viatris' current Other Current Liabilities is CHF738 Mil. Overall, Viatris has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Viatris' Other Current Liabilities compare to NBIX and UTHR?
Viatris' Other Current Liabilities of CHF738 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Viatris. Viatris's current Other Current Liabilities is CHF738 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Viatris (XSWX:VTRS) has a current Other Current Liabilities of CHF738 Mil. The stock's GF Value™ is CHF8.89, compared to a current price of CHF13.06 — trading 46.9% above its estimated fair value. The current Other Current Liabilities is CHF738 Mil. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Viatris (XSWX:VTRS), the current Other Current Liabilities is CHF738 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (XSWX:VTRS) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of CHF13.06 is trading 46.9% above its estimated GF Value™ of CHF8.89.

Key valuation signals for XSWX:VTRS:

  • Other Current Liabilities: CHF738 Mil
  • GF Value™: CHF8.89 vs. price of CHF13.06 (46.9% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the XSWX:VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score

Get the complete analysis for XSWX:VTRS

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF13.06
Price
CHF8.89
GF Value